316 related articles for article (PubMed ID: 26920949)
1. Improvement of meal-related symptoms and epigastric pain in patients with functional dyspepsia treated with acotiamide was associated with acylated ghrelin levels in Japan.
Yamawaki H; Futagami S; Kawagoe T; Maruki Y; Hashimoto S; Nagoya H; Sato H; Kodaka Y; Gudis K; Akamizu T; Sakamoto C; Iwakiri K
Neurogastroenterol Motil; 2016 Jul; 28(7):1037-47. PubMed ID: 26920949
[TBL] [Abstract][Full Text] [Related]
2. Therapy of gastroesophageal reflux disease and functional dyspepsia overlaps with symptoms after usual-dose proton pump inhibitor: Acotiamide plus usual-dose proton pump inhibitor versus double-dose proton pump inhibitor.
Takeuchi T; Takahashi Y; Kawaguchi S; Ota K; Harada S; Kojima Y; Sakamoto H; Kuramoto T; Kojima K; Sanomura M; Hoshimoto M; Higashino T; Itabashi T; Takada K; Sakaguchi M; Tominaga K; Kusano M; Higuchi K
J Gastroenterol Hepatol; 2018 Mar; 33(3):623-630. PubMed ID: 28865098
[TBL] [Abstract][Full Text] [Related]
3. Camostat Mesilate, Pancrelipase, and Rabeprazole Combination Therapy Improves Epigastric Pain in Early Chronic Pancreatitis and Functional Dyspepsia with Pancreatic Enzyme Abnormalities.
Yamawaki H; Futagami S; Kaneko K; Agawa S; Higuchi K; Murakami M; Wakabayashi M; Sakasegawa N; Kodaka Y; Ueki N; Gudis K; Kawamoto C; Iwakiri K
Digestion; 2019; 99(4):283-292. PubMed ID: 30391941
[TBL] [Abstract][Full Text] [Related]
4. Nizatidine improves clinical symptoms and gastric emptying in patients with functional dyspepsia accompanied by impaired gastric emptying.
Futagami S; Shimpuku M; Song JM; Kodaka Y; Yamawaki H; Nagoya H; Shindo T; Kawagoe T; Horie A; Gudis K; Iwakiri K; Sakamoto C
Digestion; 2012; 86(2):114-21. PubMed ID: 22846371
[TBL] [Abstract][Full Text] [Related]
5. Long-term safety and efficacy of acotiamide in functional dyspepsia (postprandial distress syndrome)-results from the European phase 3 open-label safety trial.
Tack J; Pokrotnieks J; Urbonas G; Banciu C; Yakusevich V; Bunganic I; Törnblom H; Kleban Y; Eavis P; Tsuchikawa M; Miyagawa T
Neurogastroenterol Motil; 2018 Jun; 30(6):e13284. PubMed ID: 29315999
[TBL] [Abstract][Full Text] [Related]
6. The effect of acotiamide on epigastric pain syndrome and postprandial distress syndrome in patients with functional dyspepsia.
Shinozaki S; Osawa H; Sakamoto H; Hayashi Y; Kawarai Lefor A; Yamamoto H
J Med Invest; 2016; 63(3-4):230-5. PubMed ID: 27644564
[TBL] [Abstract][Full Text] [Related]
7. Real-World, Non-Interventional, Observational Study to Evaluate Effectiveness and Tolerability of Acotiamide Hydrochloride Hydrate in Treatment of Functional Dyspepsia.
Porika SK; Veligandla KC; Muni SK; Acharya S; Mehta SC; Sharma AD
Adv Ther; 2018 Nov; 35(11):1884-1893. PubMed ID: 30350248
[TBL] [Abstract][Full Text] [Related]
8. A Randomized, Double-Blind, Pilot Study of the Effect of Famotidine on Acotiamide Treatment for Functional Dyspepsia.
Hojo M; Nagahara A; Asaoka D; Takeda T; Izumi K; Matsumoto K; Ueyama H; Shimada Y; Matsumoto K; Nojiri S; Watanabe S
Digestion; 2017; 96(1):5-12. PubMed ID: 28605740
[TBL] [Abstract][Full Text] [Related]
9. Acotiamide, a novel gastroprokinetic for the treatment of patients with functional dyspepsia: postprandial distress syndrome.
Altan E; Masaoka T; Farré R; Tack J
Expert Rev Gastroenterol Hepatol; 2012 Sep; 6(5):533-44. PubMed ID: 23061703
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic efficacy of acotiamide in patients with functional dyspepsia based on enhanced postprandial gastric accommodation and emptying: randomized controlled study evaluation by real-time ultrasonography.
Kusunoki H; Haruma K; Manabe N; Imamura H; Kamada T; Shiotani A; Hata J; Sugioka H; Saito Y; Kato H; Tack J
Neurogastroenterol Motil; 2012 Jun; 24(6):540-5, e250-1. PubMed ID: 22385472
[TBL] [Abstract][Full Text] [Related]
11. Comparison of gastric emptying and plasma ghrelin levels in patients with functional dyspepsia and non-erosive reflux disease.
Shindo T; Futagami S; Hiratsuka T; Horie A; Hamamoto T; Ueki N; Kusunoki M; Miyake K; Gudis K; Tsukui T; Iwakiri K; Sakamoto C
Digestion; 2009; 79(2):65-72. PubMed ID: 19246923
[TBL] [Abstract][Full Text] [Related]
12. A double-blind placebo controlled study of acotiamide hydrochloride for efficacy on gastrointestinal motility of patients with functional dyspepsia.
Nakamura K; Tomita T; Oshima T; Asano H; Yamasaki T; Okugawa T; Kondo T; Kono T; Tozawa K; Ohda Y; Fukui H; Kazuhito F; Hirota S; Watari J; Miwa H
J Gastroenterol; 2017 May; 52(5):602-610. PubMed ID: 27639387
[TBL] [Abstract][Full Text] [Related]
13. Clinical trial: dose-dependent therapeutic efficacy of acotiamide hydrochloride (Z-338) in patients with functional dyspepsia - 100 mg t.i.d. is an optimal dosage.
Matsueda K; Hongo M; Tack J; Aoki H; Saito Y; Kato H
Neurogastroenterol Motil; 2010 Jun; 22(6):618-e173. PubMed ID: 20059698
[TBL] [Abstract][Full Text] [Related]
14. The preproghrelin 3056 TT genotype is associated with the feeling of hunger and low acylated ghrelin levels in Japanese patients with Helicobacter pylori-negative functional dyspepsia.
Futagami S; Shimpuku M; Kawagoe T; Izumi N; Ohishi N; Yamawaki H; Shindo T; Nagoya H; Horie A; Kodaka Y; Gudis K; Itoh T; Sakamoto C
Intern Med; 2013; 52(11):1155-63. PubMed ID: 23728548
[TBL] [Abstract][Full Text] [Related]
15. Plasma levels of acylated ghrelin in patients with functional dyspepsia.
Kim YS; Lee JS; Lee TH; Cho JY; Kim JO; Kim WJ; Kim HG; Jeon SR; Jeong HS
World J Gastroenterol; 2012 May; 18(18):2231-7. PubMed ID: 22611317
[TBL] [Abstract][Full Text] [Related]
16. Plasma ghrelin and liquid gastric emptying in children with functional dyspepsia consistent with post-prandial distress syndrome.
Hijaz NM; Friesen CA; Schurman JV; Pearce RE; Abdel-Rahman SM
Neurogastroenterol Motil; 2015 Aug; 27(8):1120-6. PubMed ID: 25962328
[TBL] [Abstract][Full Text] [Related]
17. Emerging treatments in neurogastroenterology: Acotiamade, a novel treatment option for functional dyspepsia.
Matsushita M; Masaoka T; Suzuki H
Neurogastroenterol Motil; 2016 May; 28(5):631-8. PubMed ID: 26730749
[TBL] [Abstract][Full Text] [Related]
18. Acotiamide (Z-338, YM443), a new drug for the treatment of functional dyspepsia.
Tack J; Janssen P
Expert Opin Investig Drugs; 2011 May; 20(5):701-12. PubMed ID: 21417958
[TBL] [Abstract][Full Text] [Related]
19. A dose-ranging, placebo-controlled, pilot trial of Acotiamide in patients with functional dyspepsia.
Tack J; Masclee A; Heading R; Berstad A; Piessevaux H; Popiela T; Vandenberghe A; Kato H
Neurogastroenterol Motil; 2009 Mar; 21(3):272-80. PubMed ID: 19254354
[TBL] [Abstract][Full Text] [Related]
20. Acotiamide (Z-338) as a possible candidate for the treatment of functional dyspepsia.
Suzuki H; Hibi T
Neurogastroenterol Motil; 2010 Jun; 22(6):595-9. PubMed ID: 20553562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
